Olaparib approved for use in EU for pancreatic cancer

Olaparib was approved for use in patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer on the basis of the results form the Phase III POLO trial which found a progression free survival of 7.4 months for olaparib vs 3.8 months for placebo.